Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., explained in plain language.
A pharmaceutical company developing drugs, subsidiary of Simcere.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test how common drugs interact with experimental medicine Results expected Oct 2026 (estimated)
-
New hope for Platinum-Resistant ovarian cancer: BD0801 combo trial completed
Disease control CompletedThis Phase 3 trial tested whether adding the experimental drug BD0801 to standard chemotherapy can help women with recurrent ovarian cancer that no longer responds to platinum-based treatments. The study enrolled 421 participants and compared the combination to chemotherapy alone…
Phase 3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:25 UTC
-
New drug SIM0278 takes first step in human safety trial
Knowledge-focused CompletedThis early-stage trial tested the safety and tolerability of a new drug called SIM0278 in 60 healthy Chinese adults. Participants received either a single or multiple doses of the drug or a placebo via injection. The main goal was to check for side effects and how the drug moves …
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:45 UTC